Financial Performance - Moderna cut the top end of its full-year revenue forecast for a second straight quarter [1] Market Trends - New US Covid vaccine policies are hurting demand for Moderna's main product [1]

Core Viewpoint - Moderna has reduced the upper limit of its 2025 revenue forecast by $200 million due to lower-than-expected sales of its COVID-19 vaccine in the U.S. market, as access to the vaccine has been a challenge for Americans [1] Company Summary - Moderna's adjustment in revenue forecast reflects a significant impact from the sales performance of its COVID-19 vaccine [1] - The company is facing challenges related to vaccine accessibility, which has contributed to the weaker sales figures [1]

Core Insights - Moderna reported a loss in the third quarter and experienced a decline in sales as it seeks to diversify its product offerings in response to decreasing demand for its Covid-19 vaccine [1] Financial Performance - The company logged lower sales figures in the third quarter compared to previous periods, indicating a significant impact from the waning demand for its Covid-19 vaccine [1] Strategic Direction - Moderna is actively working to expand its product range to mitigate the effects of reduced demand for its primary vaccine offering [1]

Exhibit 99.1 Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected revenue range to $1.6 - $2.0 billion Improves 2025 expected GAAP operating expenses by $0.7 billion to a range of $5.2 - $5.4 billion Increases 2025 expected year-end cash balance by $0.5 billion - $1 billion to a range of $6.5 - $7.0 billion CAMBRIDGE, MA / ACCESSWIRE / November 6, 2025 / ...

Core Insights - Moderna, Inc. reported third quarter revenue of $1.0 billion, with a GAAP net loss of $(0.2) billion and a GAAP EPS of $(0.51) [1] - The company narrowed its 2025 projected revenue range to $1.6 - $2.0 billion [1] - Expected GAAP operating expenses for 2025 were improved by $0.7 billion to a range of $5.2 - $5.4 billion [1] - The expected year-end cash balance for 2025 was increased by $0.5 billion - $1 billion to a range of $6.5 - $7.0 billion [1] - CEO Stéphane Bancel highlighted strong commercial and financial performance in Q3, driven by COVID vaccine sales and cost-reduction initiatives [1]

Core Insights - Moderna (MRNA) is expected to report Q3 2025 earnings on November 6, with sales estimated at $860 million and a loss of $2.15 per share, indicating a significant decline from the previous year [1] - The consensus estimate for loss per share has widened from $9.50 to $9.74 over the past month [1] Earnings Performance - Moderna has beaten earnings estimates in the last four quarters, with an average surprise of 37.78%, including a 28.76% surprise in the last reported quarter [2][3] Revenue Expectations - The majority of Q3 revenues are anticipated to come from COVID-19 vaccines, with combined sales estimated at $762 million, reflecting a significant decline due to reduced demand for boosters [5][6] - Minimal sales of the RSV vaccine, mResvia, are expected at $30 million, significantly lower than competitors GSK's Arexvy and Pfizer's Abrysvo [7] Pipeline Developments - Moderna is developing over 40 mRNA-based candidates across various clinical stages, with a focus on updates following the recent setback in the CMV vaccine program [8] - The pivotal Phase III study for mRNA-1647 failed to meet primary efficacy endpoints, leading to its discontinuation, although it continues to be studied in mid-stage trials [9] - Investors are also focused on mRNA-1083, a COVID-19/influenza combination vaccine, which is on track for FDA resubmission [10] - Intismeran autogene, a personalized cancer therapy developed with Merck, is undergoing pivotal studies, and updates on its progress are anticipated [11] Stock Performance and Valuation - Year-to-date, Moderna's shares have decreased by 40%, underperforming the industry and the S&P 500 [13][14] - The stock is trading at a premium valuation, with a price/sales ratio of 3.14 compared to the industry average of 2.33 [16] Investment Outlook - Despite significant declines in revenue, Moderna's cash position of approximately $7.5 billion allows for continued investment in pipeline development [18] - The recent CMV vaccine setback has raised concerns about the company's growth trajectory and reliance on other late-stage assets [19][20] - Plans to launch 10 new marketed products by 2028 targeting a market exceeding $30 billion are now clouded by the CMV failure and underwhelming sales of mResvia [21] - Current premium valuation and downward revisions to earnings estimates suggest caution for investors considering building positions in Moderna stock [22]

Core Insights - Baron Health Care Fund reported a 5.39% gain in Q3 2025, slightly outperforming the Russell 3000 Health Care Index which gained 5.05% but underperforming the broader Russell 3000 Index at 8.18% [1] - The fund's performance was impacted by stock selection and negative effects from active sub-industry allocations and cash holdings during a rising market [1] Company Highlights - Roivant Sciences Ltd. (NASDAQ:ROIV) was highlighted as a key investment, achieving a one-month return of 21.59% and a 68.10% increase over the past 52 weeks, closing at $19.60 per share with a market capitalization of $13.384 billion on November 3, 2025 [2] - Roivant operates a unique business model by creating subsidiaries, or "Vants," to develop specific pipeline drugs, with notable success from its subsidiary Telavant, which sold a drug for $7.1 billion in 2023 [3] - Current promising Vants include Immunovant, which is developing a first-in-class antibody for Graves disease and rheumatoid arthritis, and Priovant, which reported positive Phase 3 results for a potential blockbuster drug [3] - Genevant, another Roivant subsidiary, focuses on lipid nanoparticle drug delivery technology and is involved in litigation with Moderna and BioNTech, with potential multi-billion-dollar implications for Roivant's balance sheet [3]

Core Viewpoint - BioNTech SE reported a significant earnings miss while exceeding revenue expectations, highlighting challenges in its financial performance and the impact of its partnerships on revenue generation [2][6]. Financial Performance - BioNTech reported an earnings per share (EPS) of -$0.14, missing the estimated EPS of $0.75, and showing a decline from the previous year's EPS of $0.81 [2][6]. - The company exceeded revenue expectations with $1.78 billion, compared to the estimated $1.09 billion, largely due to its partnership with Bristol-Myers Squibb [2][6]. - The financial metrics indicate challenges, with a negative price-to-earnings (P/E) ratio of -62.09 and an earnings yield of -1.61% [5]. Revenue Sources - Revenue gains were attributed to ongoing sales of the Comirnaty COVID vaccine and upfront payments from Bristol-Myers Squibb, although a decrease in COVID-19 vaccine sales volumes partially offset these gains [3][6]. Cost Structure - Research and development expenses increased to 564.8 million euros, while selling, general, and administrative expenses decreased to 148.5 million euros [4]. Financial Stability - BioNTech maintains a low debt-to-equity ratio of 0.015 and a strong current ratio of 8.61, indicating financial stability and a robust ability to cover short-term liabilities [5][6]. Pipeline Development - The oncology pipeline, led by pumitamig, is progressing but currently lacks best-in-class data or approvals, creating uncertainty regarding future revenue potential [4].

Core Insights - Moderna Inc's stock is experiencing a significant decline due to recent clinical setbacks overshadowing positive developments in its pipeline [1][2] - The company announced the dosing of the first patient in a Phase 1/2 study for mRNA-2808, a T-cell engager for multiple myeloma, but this was not enough to support the stock price [1] - The stock price fell 8.49% to $24.86, reflecting ongoing investor concerns [4] Clinical Developments - Moderna halted the Phase 3 trial for its cytomegalovirus vaccine, mRNA-1647, after it failed to meet its primary efficacy endpoint, leading to negative analyst reactions [2] - Analysts have adjusted their price targets, with UBS cutting its target to $40 and JPMorgan setting a target of $25 while maintaining an Underweight rating [2] Financial Outlook - The upcoming earnings report is anticipated, with consensus estimates projecting a quarterly loss of approximately $2.15 per share on revenue of about $860 million [3] - Current momentum score for Moderna is 12.67, indicating a negative price trend for the medium and long term [3]

Core Insights - Moderna, Inc. has initiated a Phase 1/2 study for its investigational mRNA-based T-cell engager, mRNA-2808, targeting relapsed or refractory multiple myeloma [1] Company Developments - The first patient has been dosed with mRNA-2808 at SCRI Oncology Partners in Nashville, Tennessee [1] - The study is being conducted in collaboration with the Sarah Cannon Research Institute [1]